ALECAlector, Inc.
This year, ALEC has to prove it can survive its cash cliff without a miracle — and the next catalyst is a dilutive capital raise on 2026-10-15, which could send the stock to $2.05 if it goes well, or tank to $0.95 if it doesn’t. The company’s fate hinges on whether it can raise cash without diluting too much, or if it’s forced to burn through its reserves and face a brutal bear path.
The Read
ALEC's stock historically reacted with a median absolute move of ~4%.
The schedule
No upcoming catalysts on the current packet.
Past
- Thu10Sep
Actual outcome: Bull · $2.03 at outcome
ALEC reported a beat on earnings with strong revenue growth, exceeding expectations and raising guidance for the next quarter. The company also announced a strategic partnership in the development of AL137-ABC, a Next-Gen Anti-Aβ therapy, which signaled progress in its pipeline and potential for future revenue streams. The stock moved higher as the positive earnings surprise and the partnership news reinforced investor confidence in the company's growth prospects and innovation capabilities.
The submission of an IND for AL137-ABC is the critical early proof point for Alector's strategic pivot to the Alector Brain Carrier (ABC) platform.
- Thu6Aug
Actual outcome: Bull · $2.09 at outcome
Alector reported a quarterly loss of $0.21 per share, matching the estimate, but showed progress on its ABC platform with AL137 advancing as its lead anti-amyloid beta antibody program for Alzheimer's. The stock rallied on continued development momentum and positive guidance on its pipeline, despite the EPS miss.
Alector's Q2 print will force a reckoning on its shrinking cash runway following the AL101 clinical failure.
- Thu7May
Actual outcome: Bear · $2.30 at outcome
Alector shares fell 5.7% following its Q1 report, driven by a revenue miss despite an in-line EPS loss of $0.21. The negative sentiment was heavily compounded by the recent discontinuation of its Phase 2 PROGRESS-AD trial for AL101 due to futility, which removed a major pipeline catalyst and overshadowed updates on the company's early-stage ABC platform.
Q1 2026 results and an update on AL101 enrollment will be investors’ first detailed look at how Alector is executing post-AL001, with the focus on cash burn discipline, collaboration revenue visibility, and whether AL101 timelines remain intact.
- Wed15Apr
Actual outcome: Bear · $2.41 at outcome
Alector failed to secure a viable regulatory path forward for AL001 (latozinemab) in frontotemporal dementia, effectively sunsetting the asset in favor of its earlier-stage Alector Brain Carrier (ABC) platform. The loss of this near-term clinical catalyst and the resulting write-off of AL001's value disappointed investors, driving an initial 6.6% decline that ultimately pushed shares below the $1.60 bear floor in the following months.
High-stakes decision on the residual path for AL001 (latozinemab) in frontotemporal dementia, clarifying whether regulators and Alector see any viable path forward or whether the asset is effectively sunset in favor of the Alector Brain Carrier (ABC) platform. At a base price of $2.47, a constructive outcome that preserves optionality or unlocks partnering value could support a move toward $3.10, while a clear write-off or lack of strategic clarity risks a retrace toward $3.10.
- Wed25Feb
Actual outcome: Bull · $2.11 at outcome
Alector met EPS estimates and beat revenue expectations while successfully pivoting its strategic focus to the Alector Brain Carrier (ABC) platform and confirming a cash runway through 2027. Despite initial volatility following the previous year's clinical failure, the update demonstrated disciplined cost management and pipeline progress that supported a recovery toward the bull target.
First financial update following the late 2025 Phase 3 AL001 (Latozinemab) clinical failure and the 49% workforce reduction. Focus will be on new cash burn rate, confirmation of cash runway through 2027, and strategic priority shift to AL101 and the ABC platform.
